Patent EA-002033-B1 (EA)
Title: Nitric oxide synthase inhibitors
Inventor: BEAMS RICHARD MANSFIELD
IPC: C07C319/20
Filed: 1998-01-09
Abstract: 1. A compound of formula (I);   or a salt, solvate, or physiologically functional derivative thereof. 2. A compound of formula (I) selected from: (R/S)-[2-(1 -iminoethylamino)ethyl]-DL-homocysteine (S)-[2-(I -iminoethylamino)ethylj-L-homocysteine; and (R)-[2-(1 -iminoethylamino)ethyl]-D-homocysteine or a salt, solvate, or physiologically functional derivative thereof. 3. The compound of formula (I) which is (S)-[2-(1-iminoethylamino)ethyl]-L- homocysteine or a salt, solvate or physiologically functional derivative thereof. 4. A method for the prophylaxis or treatment of a clinical condition in a mammal, such as a human, for which an inhibitor of nitric oxide synthase is indicated, which comprises administration of a therapeutically effective amount of a compound of formula (I) as defined in any of claims I to 3, or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof. 5. A method according to claim 4 wherein the clinical condition is selected from arthritis, asthma, ileus, and migraine. 6. A compound of formula (I) as defined in any of claims 1 to 3 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for use in medical therapy. 7. A pharmaceutical formulation comprising a compound of formula (I) as defined in any of claims I to 3 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients. 8. Use of a compound of formula (I) as defined in any of claims 1 to 3 or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof in the manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of nitric oxide synthase is indicated. 9. Use according to claim 8 wherein the clinical condition is selected from arthritis, asthma, ileus, and migraine. 10. A process for preparing a compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof which comprises: (i) reaction of the compound of formula (II)   or an enantiomer, a salt, or a protected derivative thereof, with a compound of formula (III)   or a salt thereof, wherein L is a leaving group; followed by the following steps in any order: (ii) optional removal of any protecting groups; (iii) optional separation of an enantiomer from a mixture of enantiomers; (iv) optional conversion of the product to a corresponding salt, solvate or physiologically functional derivative thereof. 11. A compound selected from: (R,S)-7N-benzyloxycarbonyl-2,7-diamino-5-thioheptanoic acid; (S)-2N-t-butoxycarbonyl-2,7-diamino-5-thioheptanoic acid; (S)-t-butyl-2N-t-butoxycarbonyl-7N-benzyloxycarbonyl-2,7-diamino-5- thioheptanoate;  (S)-t-butyl-2N-t-butoxycarbonyl-2,7-diamino-5-thioheptanoate; (R,S)-t-butyl-2N-t-butoxycarbonyl-7N-benzyloxycarbonyl-2,7-diamino-5- thioheptanoate; and (R,S)-t-butyl-2N-t-butoxycarbonyl-2 ,7-diamino-5-thioheptanoate.